(Q35201017)

7 August 2017

1 reference

title

Management of the negative symptoms of schizophrenia: new treatment options (English)

1 reference

7 August 2017

0 references

1

Hans-Jürgen Möller

1 reference

7 August 2017

publication date

1 January 2003

1 reference

7 August 2017

1 reference

7 August 2017

volume

17

1 reference

7 August 2017

issue

11

1 reference

7 August 2017

page(s)

793-823

1 reference

Fluoxetine and side effects

7 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00023210-200317110-00003

Effects of atypical neuroleptics on sustained attention deficits in schizophrenia: a trial of risperidone versus haloperidol

21 January 2018

1 reference

12 December 2020

Efficacy of olanzapine: an overview of pivotal clinical trials

1 reference

12 December 2020

D-serine added to clozapine for the treatment of schizophrenia

1 reference

12 December 2020

Molecular pathology of schizophrenia: more than one disease process?

1 reference

12 December 2020

Clinical, EEG mapping and psychometric studies in negative schizophrenia: comparative trials with amisulpride and fluphenazine

1 reference

12 December 2020

Positive and negative schizophrenic symptoms and the role of dopamine

1 reference

12 December 2020

Amisulpride versus haloperidol in treatment of schizophrenic patients--results of a double-blind study

1 reference

12 December 2020

Negative symptoms in schizophrenia: a target for new drug development

1 reference

12 December 2020

Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia

1 reference

12 December 2020

Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study

1 reference

12 December 2020

Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group

1 reference

12 December 2020

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

1 reference

12 December 2020

A standardized psychiatric assessment scale for rating chronic psychotic patients

1 reference

12 December 2020

A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study

1 reference

12 December 2020

A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia

1 reference

12 December 2020

Differential changes in serotonin 5-HT1A and 5-HT2 receptor binding in patients with chronic schizophrenia

1 reference

12 December 2020

Effect of pimozide on positive and negative symptoms in schizophrenic patients: are negative symptoms state dependent?

1 reference

12 December 2020

Implications of the efficacy of thiothixene and a chlorpromazine- imipramine combination for depression in schizophrenia

1 reference

12 December 2020

Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials

1 reference

12 December 2020

Neuroleptic-induced parkinsonism in older schizophrenics

1 reference

12 December 2020

Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group).

1 reference

12 December 2020

Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group

1 reference

12 December 2020

Carbamazepine diminishes the sensitivity of the plasma arginine vasopressin response to osmotic stimulation

1 reference

12 December 2020

1 reference

12 December 2020

Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study

1 reference

12 December 2020

Effects of Catechol Estrogens1and Catecholamines on Hypothalamic and Corpus Striatal Tyrosine Hydroxylase Activity

1 reference

12 December 2020

NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders

1 reference

12 December 2020

Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia

1 reference

12 December 2020

Biochemical findings of negative symptoms in schizophrenia and their putative relevance to pharmacologic treatment. A review

1 reference

12 December 2020

Effect of neuroleptics on positive and negative symptoms and the deficit state

1 reference

12 December 2020

Zotepine in the treatment of schizophrenic patients with prevailingly negative symptoms. A double-blind trial vs. haloperidol

1 reference

12 December 2020

Dosing the antipsychotic medication olanzapine

1 reference

12 December 2020

A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia

1 reference

12 December 2020

Fluoxetine as an Adjunct to Conventional Antipsychotic Treatment of Schizophrenia Patients with Residual Symptoms

1 reference

12 December 2020

The role of estrogen in schizophrenia.

1 reference

12 December 2020

Zotepine vs. haloperidol in paranoid schizophrenia: a double-blind trial

1 reference

12 December 2020

Neuroleptic treatment of negative symptoms in schizophrenic patients. Efficacy problems and methodological difficulties

1 reference

12 December 2020

Serotonin-dopamine interaction and its relevance to schizophrenia

1 reference

12 December 2020

Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia.

1 reference

12 December 2020

NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers.

1 reference

12 December 2020

The use of antidepressants for negative symptoms in a subset of schizophrenic patients

1 reference

12 December 2020

Risperidone-induced increase of plasma norepinephrine is not correlated with symptom improvement in chronic schizophrenia

1 reference

12 December 2020

Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group.

1 reference

12 December 2020

Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients

1 reference

12 December 2020

Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials

1 reference

12 December 2020

Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis.

1 reference

12 December 2020

Carbamazepine augmentation for schizophrenia: how good is the evidence?

1 reference

12 December 2020

Indirect modulation of dopamine D2 receptors as potential pharmacotherapy for schizophrenia: II. Glutamate (Ant)agonists

1 reference

12 December 2020

The role of estrogens in schizophrenia gender differences

1 reference

12 December 2020

The two-syndrome concept: origins and current status

1 reference

12 December 2020

Generating and testing a causal explanation of the gender difference in age at first onset of schizophrenia

1 reference

12 December 2020

Effectiveness and tolerance of zotepine in a double-blind comparison with perazine in schizophrenic patients

1 reference

12 December 2020

Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients

1 reference

12 December 2020

Carbamazepine as an adjunct of antipsychotic therapy

1 reference

12 December 2020

Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group

1 reference

12 December 2020

Comments on article by Tran and colleagues, "Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders"

1 reference

12 December 2020

Lithium addition to neuroleptic treatment in chronic schizophrenia: a randomized, double-blind, placebo-controlled, cross-over study.

1 reference

12 December 2020

Treatment of negative symptoms

1 reference

12 December 2020

Negative v positive schizophrenia. Definition and validation

1 reference

12 December 2020

Activation of forebrain dopamine systems by phencyclidine and footshock stress: evidence for distinct mechanisms

1 reference

12 December 2020

Psychosocial skills training for schizophrenia: lessons from the laboratory

1 reference

12 December 2020

A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia

1 reference

12 December 2020

Risperidone in the treatment of schizophrenia

1 reference

12 December 2020

A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: a parallel-group double-blind trial

1 reference

12 December 2020

Behavioural evidence for a functional interaction between central 5-HT2 and 5-HT1A receptors

1 reference

12 December 2020

Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations.

1 reference

12 December 2020

Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia

1 reference

12 December 2020

Antidepressant Usage in Schizophrenia

1 reference

12 December 2020

Correlation between reduced in vivo benzodiazepine receptor binding and severity of psychotic symptoms in schizophrenia

1 reference

12 December 2020

Antipsychotic drug effects on motor activation measured by functional magnetic resonance imaging in schizophrenic patients.

1 reference

12 December 2020

A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia

1 reference

12 December 2020

A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia

1 reference

12 December 2020

A revised excitotoxic hypothesis of schizophrenia: therapeutic implications

1 reference

12 December 2020

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group

1 reference

12 December 2020

Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial

1 reference

12 December 2020

Atypical neuroleptics: a new approach in the treatment of negative symptoms

1 reference

12 December 2020

Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial

1 reference

12 December 2020

Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis

1 reference

12 December 2020

Elevation of plasma concentrations of haloperidol after the addition of fluoxetine

1 reference

12 December 2020

Clinical effectiveness of zotepine in treatment of negative schizophrenic symptoms. Results of an open and a double-blind controlled trial

1 reference

12 December 2020

Amelioration of negative symptoms in schizophrenia by glycine.

1 reference

12 December 2020

Vasopressin (DDAVP) therapy in chronic schizophrenia: effects on negative symptoms and memory.

1 reference

12 December 2020

A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia.

1 reference

12 December 2020

Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant

1 reference

12 December 2020

Glutamatergic mechanisms in schizophrenia

1 reference

12 December 2020

Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors

1 reference

12 December 2020

Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial.

1 reference

12 December 2020

Citalopram as an adjuvant in schizophrenia: further evidence for a serotonergic dimension in schizophrenia

1 reference

12 December 2020

Adjunctive fluoxetine improves global function in chronic schizophrenia.

1 reference

12 December 2020

Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group

1 reference

12 December 2020

A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report.

1 reference

12 December 2020

Investigation of a possible diencephalic pathology in schizophrenia

1 reference

12 December 2020

Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial.

1 reference

12 December 2020

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

1 reference

12 December 2020

Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials

1 reference

12 December 2020

A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia

1 reference

12 December 2020

A rating scale for emotional blunting

1 reference

12 December 2020

Negative symptoms in schizophrenia: considerations for clinical trials. Working group on negative symptoms in schizophrenia

1 reference

12 December 2020

Effect of chronic estradiol and haloperidol treatment on striatal dopamine receptors

1 reference

12 December 2020

Amisulpride: efficacy in the management of chronic patients with predominant negative symptoms of schizophrenia

1 reference

12 December 2020

The initial prodrome in schizophrenia: searching for naturalistic core dimensions of experience and behavior

1 reference

12 December 2020

Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.

1 reference

12 December 2020

Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients

1 reference

12 December 2020

D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study

1 reference

12 December 2020

Predictors of response to lithium in patients with psychoses

1 reference

12 December 2020

A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients

1 reference

12 December 2020

Estrogen - a potential treatment for schizophrenia.

1 reference

12 December 2020

Periodic psychosis recurring in association with menstrual cycle

1 reference

12 December 2020

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia

1 reference

12 December 2020

Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia

1 reference

12 December 2020

Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial

1 reference

12 December 2020

Further evidence for a specific role of estradiol in schizophrenia?

1 reference

12 December 2020

Treatment of schizophrenia 1999. The expert consensus guideline series

1 reference

12 December 2020

A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study

1 reference

12 December 2020

The diagnosis and understanding of schizophrenia. Part III. Speculations on the processes that underlie schizophrenic symptoms and signs.

1 reference

12 December 2020

Antidepressants in 'depressed' schizophrenic inpatients. A controlled trial.

1 reference

12 December 2020

Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group

1 reference

12 December 2020

Mesolimbic and mesocortical dopamine activation induced by phencyclidine: contrasting pattern to striatal response

1 reference

12 December 2020

NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine.

1 reference

12 December 2020

Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia

1 reference

12 December 2020

The concept of negative symptoms

1 reference

12 December 2020

Comparison of phencyclidine hydrochloride (Sernyl) with other drugs. Simulation of schizophrenic performance with phencyclidine hydrochloride (Sernyl), lysergic acid diethylamide (LSD-25), and amobarbital (Amytal) sodium; II. Symbolic and sequential

1 reference

12 December 2020

Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.

1 reference

12 December 2020

Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.

1 reference

12 December 2020

Mirtazapine enhances the effect of haloperidol on apomorphine-induced climbing behaviour in mice and attenuates haloperidol-induced catalepsy in rats

1 reference

12 December 2020

Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients

1 reference

12 December 2020

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

1 reference

12 December 2020

A double-blind trial of carbamazepine in negative symptom schizophrenia.

1 reference

12 December 2020

Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial

1 reference

12 December 2020

Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group

1 reference

12 December 2020

Placebo-controlled trial of glycine added to clozapine in schizophrenia

1 reference

12 December 2020

Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia.

1 reference

12 December 2020

Clozapine effects on positive and negative symptoms: a six-month trial in treatment-refractory schizophrenics

1 reference

12 December 2020

Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations

1 reference

12 December 2020

The relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine.

1 reference

12 December 2020

Testosterone as well as estrogen increases serotonin2A receptor mRNA and binding site densities in the male rat brain

1 reference

12 December 2020

Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate

1 reference

12 December 2020

Fluoxetine augmentation of clozapine treatment in patients with schizophrenia

1 reference

12 December 2020

Serotonin, schizophrenia and antipsychotic drug action

1 reference

12 December 2020

Piracetam in the treatment of schizophrenia: implications for the glutamate hypothesis of schizophrenia

1 reference

12 December 2020

Ritanserin, a 5-HT2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition

1 reference

12 December 2020

Reboxetine add on therapy to haloperidol in the treatment of schizophrenia: a preliminary double-blind randomized placebo-controlled study

1 reference

12 December 2020

Negative symptoms in schizophrenia. Definition and reliability

1 reference

12 December 2020

Topiramate improves deficit symptoms in a patient with schizophrenia when added to a stable regimen of antipsychotic medication.

1 reference

12 December 2020

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

1 reference

12 December 2020

ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group

1 reference

12 December 2020

Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine.

1 reference

12 December 2020

The positive-negative distinction in schizophrenia. Review of natural history validators

1 reference

12 December 2020

Treatment of negative symptoms in schizophrenia with amisulpride

1 reference

12 December 2020

Possible adverse drug interactions between fluoxetine and other psychotropics

1 reference

12 December 2020

A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder

1 reference

12 December 2020

Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia

1 reference

12 December 2020

One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol

1 reference

12 December 2020

Abnormal excitatory neurotransmitter metabolism in schizophrenic brains

1 reference

12 December 2020

Double-blind comparison of 3 x 75 mg zotepine und 3 x 4 mg haloperidol in acute schizophrenic patients

1 reference

12 December 2020

Calcium-calmodulin systems in psychopharmacology and synaptic modulation

1 reference

12 December 2020

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

1 reference

12 December 2020

Dimensions of outcome with clozapine

1 reference

12 December 2020

Improvement of some schizophrenic deficit symptoms with low doses of amisulpride

1 reference

12 December 2020

Depression, parkinsonian symptoms, and negative symptoms in schizophrenics treated with neuroleptics

1 reference

12 December 2020

Amisulpride: a review of its efficacy in schizophrenia

1 reference

12 December 2020

Pimozide treatment of the negative schizophrenic syndrome: an open trial.

1 reference

12 December 2020

The emerging role of glutamate in the pathophysiology and treatment of schizophrenia

1 reference

12 December 2020

Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia

1 reference

12 December 2020

Effect of carbamazepine on dopamine release and reuptake in rat striatal slices

1 reference

12 December 2020

Antischizophrenic drugs of the diphenylbutylpiperidine type act as calcium channel antagonists

1 reference

12 December 2020

An animal model for the effects of estradiol on dopamine-mediated behavior: implications for sex differences in schizophrenia

1 reference

12 December 2020

Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.

1 reference

12 December 2020

Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group

1 reference

12 December 2020

Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine

1 reference

12 December 2020

1 reference

12 December 2020

Efficacy of beta-blocker supplementation for schizophrenia: a systematic review of randomized trials

1 reference

12 December 2020

Definition, psychopharmacological basis and clinical evaluation of novel/atypical neuroleptics: methodological issues and clinical consequences

1 reference

12 December 2020

Antidepressant drugs in anergic schizophrenia. A double-blind cross-over study with maprotiline and placebo

1 reference

12 December 2020

Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia.

1 reference

12 December 2020

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

1 reference

12 December 2020

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

12 December 2020

Is platelet release of 2-arachidonoyl-glycerol a mediator of cognitive deficits? An endocannabinoid theory of schizophrenia and arousal

1 reference

12 December 2020

The role of serotonin in antipsychotic drug action

1 reference

12 December 2020

Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group

1 reference

12 December 2020

Affective, schizoaffective and schizophrenic psychoses. A comparative long-term study

1 reference

12 December 2020

Treatment of secondary depression in schizophrenia. A double-blind, placebo-controlled trial of amitriptyline added to perphenazine

1 reference

12 December 2020

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

1 reference

12 December 2020

Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study

1 reference

12 December 2020

10.2165/00023210-200317110-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

7 August 2017

1030602129

0 references

1 reference